Request Free Sample ×
UK Custom Antibody Market Research Report- Forecast To 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

UK Custom Antibody Market

ID: MRFR/HC/51846-HCR
200 Pages
Rahul Gotadki
Last Updated: February 06, 2026

UK Custom Antibody Market Research Report By Service (Antibody Development, Antibody Production & Purification, Antibody Fragmentation & Labelling), By Source (Mice, Others), By Research Area (Oncology, Neurobiology, Infectious Diseases, Immunology, Others), By Type (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Antibody, Other Custom Antibodies) and By End Users (Hospitals & Clinics, Academic & Research Institute, Contact Research Organization, Biotechnology Companies, Others) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

UK Custom Antibody Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Life Sciences, BY Service (USD Million)
  49.     4.1.1 Antibody Development
  50.     4.1.2 Antibody Production & Purification
  51.     4.1.3 Antibody Fragmentation & Labelling
  52.   4.2 Life Sciences, BY Source (USD Million)
  53.     4.2.1 Mice
  54.     4.2.2 Others
  55.   4.3 Life Sciences, BY Research Area (USD Million)
  56.     4.3.1 Oncology
  57.     4.3.2 Neurobiology
  58.     4.3.3 Infectious Diseases
  59.     4.3.4 Immunology
  60.     4.3.5 Others
  61.   4.4 Life Sciences, BY Type (USD Million)
  62.     4.4.1 Monoclonal Antibodies
  63.     4.4.2 Polyclonal Antibodies
  64.     4.4.3 Recombinant Antibody
  65.     4.4.4 Other Custom Antibodies
  66.   4.5 Life Sciences, BY End Users (USD Million)
  67.     4.5.1 Biotechnology Companies
  68.     4.5.2 Hospital & Clinics
  69.     4.5.3 Academic & Research Institutes
  70.     4.5.4 Contract Research Organizations
  71.     4.5.5 Others
  72. 5 SECTION V: COMPETITIVE ANALYSIS
  73.   5.1 Competitive Landscape
  74.     5.1.1 Overview
  75.     5.1.2 Competitive Analysis
  76.     5.1.3 Market share Analysis
  77.     5.1.4 Major Growth Strategy in the Life Sciences
  78.     5.1.5 Competitive Benchmarking
  79.     5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  80.     5.1.7 Key developments and growth strategies
  81.       5.1.7.1 New Product Launch/Service Deployment
  82.       5.1.7.2 Merger & Acquisitions
  83.       5.1.7.3 Joint Ventures
  84.     5.1.8 Major Players Financial Matrix
  85.       5.1.8.1 Sales and Operating Income
  86.       5.1.8.2 Major Players R&D Expenditure. 2023
  87.   5.2 Company Profiles
  88.     5.2.1 Thermo Fisher Scientific (US)
  89.       5.2.1.1 Financial Overview
  90.       5.2.1.2 Products Offered
  91.       5.2.1.3 Key Developments
  92.       5.2.1.4 SWOT Analysis
  93.       5.2.1.5 Key Strategies
  94.     5.2.2 Abcam (GB)
  95.       5.2.2.1 Financial Overview
  96.       5.2.2.2 Products Offered
  97.       5.2.2.3 Key Developments
  98.       5.2.2.4 SWOT Analysis
  99.       5.2.2.5 Key Strategies
  100.     5.2.3 GenScript (CN)
  101.       5.2.3.1 Financial Overview
  102.       5.2.3.2 Products Offered
  103.       5.2.3.3 Key Developments
  104.       5.2.3.4 SWOT Analysis
  105.       5.2.3.5 Key Strategies
  106.     5.2.4 Merck KGaA (DE)
  107.       5.2.4.1 Financial Overview
  108.       5.2.4.2 Products Offered
  109.       5.2.4.3 Key Developments
  110.       5.2.4.4 SWOT Analysis
  111.       5.2.4.5 Key Strategies
  112.     5.2.5 Bio-Rad Laboratories (US)
  113.       5.2.5.1 Financial Overview
  114.       5.2.5.2 Products Offered
  115.       5.2.5.3 Key Developments
  116.       5.2.5.4 SWOT Analysis
  117.       5.2.5.5 Key Strategies
  118.     5.2.6 Cell Signaling Technology (US)
  119.       5.2.6.1 Financial Overview
  120.       5.2.6.2 Products Offered
  121.       5.2.6.3 Key Developments
  122.       5.2.6.4 SWOT Analysis
  123.       5.2.6.5 Key Strategies
  124.     5.2.7 Santa Cruz Biotechnology (US)
  125.       5.2.7.1 Financial Overview
  126.       5.2.7.2 Products Offered
  127.       5.2.7.3 Key Developments
  128.       5.2.7.4 SWOT Analysis
  129.       5.2.7.5 Key Strategies
  130.     5.2.8 R&D Systems (US)
  131.       5.2.8.1 Financial Overview
  132.       5.2.8.2 Products Offered
  133.       5.2.8.3 Key Developments
  134.       5.2.8.4 SWOT Analysis
  135.       5.2.8.5 Key Strategies
  136.     5.2.9 Sigma-Aldrich (US)
  137.       5.2.9.1 Financial Overview
  138.       5.2.9.2 Products Offered
  139.       5.2.9.3 Key Developments
  140.       5.2.9.4 SWOT Analysis
  141.       5.2.9.5 Key Strategies
  142.   5.3 Appendix
  143.     5.3.1 References
  144.     5.3.2 Related Reports
  145. 6 LIST OF FIGURES
  146.   6.1 MARKET SYNOPSIS
  147.   6.2 UK MARKET ANALYSIS BY SERVICE
  148.   6.3 UK MARKET ANALYSIS BY SOURCE
  149.   6.4 UK MARKET ANALYSIS BY RESEARCH AREA
  150.   6.5 UK MARKET ANALYSIS BY TYPE
  151.   6.6 UK MARKET ANALYSIS BY END USERS
  152.   6.7 KEY BUYING CRITERIA OF LIFE SCIENCES
  153.   6.8 RESEARCH PROCESS OF MRFR
  154.   6.9 DRO ANALYSIS OF LIFE SCIENCES
  155.   6.10 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
  156.   6.11 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
  157.   6.12 SUPPLY / VALUE CHAIN: LIFE SCIENCES
  158.   6.13 LIFE SCIENCES, BY SERVICE, 2024 (% SHARE)
  159.   6.14 LIFE SCIENCES, BY SERVICE, 2024 TO 2035 (USD Million)
  160.   6.15 LIFE SCIENCES, BY SOURCE, 2024 (% SHARE)
  161.   6.16 LIFE SCIENCES, BY SOURCE, 2024 TO 2035 (USD Million)
  162.   6.17 LIFE SCIENCES, BY RESEARCH AREA, 2024 (% SHARE)
  163.   6.18 LIFE SCIENCES, BY RESEARCH AREA, 2024 TO 2035 (USD Million)
  164.   6.19 LIFE SCIENCES, BY TYPE, 2024 (% SHARE)
  165.   6.20 LIFE SCIENCES, BY TYPE, 2024 TO 2035 (USD Million)
  166.   6.21 LIFE SCIENCES, BY END USERS, 2024 (% SHARE)
  167.   6.22 LIFE SCIENCES, BY END USERS, 2024 TO 2035 (USD Million)
  168.   6.23 BENCHMARKING OF MAJOR COMPETITORS
  169. 7 LIST OF TABLES
  170.   7.1 LIST OF ASSUMPTIONS
  171.     7.1.1
  172.   7.2 UK MARKET SIZE ESTIMATES; FORECAST
  173.     7.2.1 BY SERVICE, 2025-2035 (USD Million)
  174.     7.2.2 BY SOURCE, 2025-2035 (USD Million)
  175.     7.2.3 BY RESEARCH AREA, 2025-2035 (USD Million)
  176.     7.2.4 BY TYPE, 2025-2035 (USD Million)
  177.     7.2.5 BY END USERS, 2025-2035 (USD Million)
  178.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  179.     7.3.1
  180.   7.4 ACQUISITION/PARTNERSHIP
  181.     7.4.1

UK Life Sciences Market Segmentation

Life Sciences By Service (USD Million, 2025-2035)

  • Antibody Development
  • Antibody Production & Purification
  • Antibody Fragmentation & Labelling

Life Sciences By Source (USD Million, 2025-2035)

  • Mice
  • Others

Life Sciences By Research Area (USD Million, 2025-2035)

  • Oncology
  • Neurobiology
  • Infectious Diseases
  • Immunology
  • Others

Life Sciences By Type (USD Million, 2025-2035)

  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Recombinant Antibody
  • Other Custom Antibodies

Life Sciences By End Users (USD Million, 2025-2035)

  • Biotechnology Companies
  • Hospital & Clinics
  • Academic & Research Institutes
  • Contract Research Organizations
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓